US DoD Travelan Clinical Update
Filed with ASX · · 2 pages · English
Key Points • Manufacture of investigational medical products to support the Uniformed Services University (USU)clinical programto evaluate the efficacy of Travelan® and two other non- antibiotic OTC products inTravelers’Diarrheainitiated • USU are anticipating an enrolment start date of April 2022 and plan to enrol 1336 participants in total Melbourne, Australia, November 15, 2021: Immuron Limited
Earlier from Immuron
- US DoD Naval Medical Research Center Clinical Update
- IMM124E Demonstrates Antiviral T-Cell Immunity
- Reinstatement to Official Quotation
- Immuron planned Acquisition of R&D Vaccine Company
- Preliminary Final Report
Later from Immuron
- Immuron Receives European Patent on Drug to Treat Diarrhea
- Response to ASX Query
- Half Yearly Report and Accounts
- Immuron Q3 Global Sales up 216% YoY
- Appointment of Mr Steven Lydeamore as Chef Executive Officer
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron